9 results about "Drug encapsulation" patented technology

The present invention relates to a continuous ultrasonic reactor capable of performing continuous chemical reactions using multiple ultrasonic generators installed in parallel. The reactor body includes a reactant inlet and a product outlet, and the ultrasonic generators are uniformly arranged inside the reactor to induce mixing of reactants and the generation of free radicals through ultrasonic cavitation. As a result, the reaction can be effectively initiated without the use of a chemical initiator, and the reaction speed and efficiency are significantly improved. In addition, a cooling jacket is installed on the exterior of the reactor to stably maintain the reaction temperature, thereby ensuring uniformity of reaction conditions. The operating conditions of the ultrasonic generators can be adjusted via a control panel, allowing for flexible application to various chemical reaction processes. The present invention can be utilized in high-efficiency chemical processes such as polymer polymerization, nanoparticle synthesis, and drug encapsulation, and is an innovative technology that simultaneously provides energy efficiency and eco-friendliness.

This invention discloses a method for preparing avermectin nanoparticles supported on zein-sodium lignin sulfonate, and its applications. The preparation method involves dissolving avermectin and zein in an organic solvent to form a solution (stream 1), and dissolving sodium lignin sulfonate or modified sodium lignin sulfonate in deionized water to form a solution (stream 2). Both streams are simultaneously injected into a dual-channel confined counter-current mixer for rapid mixing. The resulting nanoparticle suspension is then collected, completing the preparation process. This invention utilizes the compatibility of hydrophobic zein with avermectin, combined with the self-assembly properties of zein and the use of sodium lignin sulfonate or modified sodium lignin sulfonate as a stabilizer, to prepare avermectin nanoparticles with high drug encapsulation efficiency and excellent drug release performance. Furthermore, these nanoparticles exhibit excellent resistance to UV photodegradation, effectively reducing the photodegradation of avermectin. The method is simple, rapid, and easy to control.

A liposome of a nitrogen-containing heterocyclic compound comprises the following components: a nitrogen-containing heterocyclic compound as shown in compound 3 below and a lipid component. The liposomes of the present invention satisfy one or more of the following advantages: (1) small particle size and uniform distribution; (2) high API content; (3) high drug encapsulation efficiency; (4) good stability; (5) good antitumor activity; (6) good safety; and (7) long-lasting effect.

This invention relates to a method for preparing resveratrol nanoparticles, belonging to the field of traditional Chinese medicine technology. Addressing the problems of low oral bioavailability and lack of colonic targeting of resveratrol, this invention provides a nanoparticle formulation composed of resveratrol, zein, and xylan. The formulation is prepared by dissolving resveratrol and zein in an organic phase, adding them dropwise to an aqueous xylan phase, and then evaporating the organic solvent. This invention utilizes the hydrophobic effect of zein to improve drug encapsulation efficiency and leverages the colonic degradation characteristics and anti-inflammatory activity of xylan to achieve synergistic effects, enabling precise release of resveratrol at sites of intestinal inflammation.

This invention discloses a ginsenoside-modified ceramide liposome, its preparation method, and its application, belonging to the field of cosmetic preparation technology. The liposome is composed of ceramide, phosphatidylcholine, ginsenoside Rg3, and water. Addressing the shortcomings of existing ceramide liposomes, such as poor physical stability and low transdermal absorption, this invention innovatively utilizes the unique amphiphilic molecular structure of ginsenoside Rg3, embedding it as a functional modifier into the liposome bilayer. The hydrophobic steroidal backbone of Rg3 is tightly bound to the lipid tail through hydrophobic interactions, with the hydrophilic sugar chains facing the aqueous phase. This not only acts as a "molecular anchor," significantly enhancing the density of the lipid bilayer and improving the physical stability and drug encapsulation efficiency of the liposome, but also endows the liposome with excellent antioxidant, anti-inflammatory, and skin microcirculation-promoting bioactivity. The liposomes prepared by this invention achieve deep transdermal delivery and long-lasting release of ceramides, effectively repairing damaged skin barriers; and utilize the bioactivity of Rg3 to achieve multiple effects of moisturizing, anti-aging, and repair. The preparation method of this invention is simple, mild, and reproducible. The resulting product can be widely used in the preparation of various skin care products such as creams, lotions, and serums, and has significant market application prospects.

This invention discloses a method for preparing and studying the drug-loading properties of PEGMA-g-PEGMA-b-PCL polymer micelles, belonging to the field of drug carrier technology. The method first synthesizes a triblock graft copolymer using the ATRP method, then completes micelle self-assembly through solution dropwise addition, rotary evaporation, and membrane filtration. Using a hydrophobic antitumor drug as a model, drug-loaded micelles are prepared, and drug loading, release, stability, and cytotoxicity are simultaneously tested. This invention designs a hydrophilic grafted PEGMA-g-PEGMA structure and optimizes the preparation process parameters. The resulting micelles have a spherical core-shell structure with a particle size of 80-180 nm, exhibiting good self-assembly stability and pH response characteristics. The drug loading is ≥8.5%, the encapsulation efficiency is ≥80%, drug release is slow under physiological conditions, and the cumulative drug release rate in the tumor microenvironment is 75%-90% after 72 hours. Furthermore, it exhibits good storage stability and excellent biocompatibility, enabling efficient drug encapsulation and tumor microenvironment-responsive release. This method has significant application value in the preparation of targeted therapeutic carriers for hydrophobic antitumor drugs.

The application relates to the technical field of high polymer composite materials, and provides a composite microsphere, which comprises a core body and a coating layer covering the core body, the core body comprises doped hydroxyapatite doped with zinc ions and cerium ions, the coating layer comprises polylactic acid and beta-cyclodextrin, and graphene oxide is distributed between the core body and the coating layer; the composite microsphere has a porous structure, and beta-cyclodextrin is filled in at least part of the porous structure. The composite microsphere provided by the application can significantly improve the drug encapsulation performance of the composite microsphere by utilizing the synergistic effect among the Ce / Zn co-doped doped hydroxyapatite, polylactic acid, graphene oxide and beta-cyclodextrin, can effectively inhibit and reduce the initial burst release phenomenon of the drug, and can construct a stable, long-acting and controllable drug sustained-release system.

According to the present invention, it is possible to provide a drug carrier having excellent bioavailability and improved drug encapsulation efficiency by preparing lipoprotein-mimicking solid lipid nanoparticles having a core-shell structure consisting of albumin-conjugated cholesterol, a fusogenic lipid, a cationic lipid, a triglyceride and a cholesteryl ester.